Last reviewed · How we verify
CKD-386
At a glance
| Generic name | CKD-386 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg (PHASE1)
- Clinical Trial to Evaluate the Efficacy and Safety of CKD-386 (PHASE3)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) (PHASE1)
- A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386 (PHASE1)
- A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-386 CI brief — competitive landscape report
- CKD-386 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI